论文部分内容阅读
目的:观察舒肝解郁胶囊治疗卒中后抑郁的疗效和副反应。方法:将120例卒中后抑郁病人随机分为治疗组和对照组,两组病人均给予脑梗死常规治疗,治疗组服用舒肝解郁胶囊,对照组服用氟西汀胶囊,疗程8周。分别于治疗前,治疗第2,4,8周末采用汉密尔顿抑郁量表(HAMD)、副反应量表(TESS)评定疗效和不良反应。结果:至研究终点,两组HAMD评分均显著低于治疗前(P<0.05),但两组间比较差异无统计学意义(P>0.05);治疗组和对照组有效率分别为86.67%,83.33%,差异无统计学意义(P>0.05);治疗组的TESS评分显著低于对照组(P<0.05)。结论:舒肝解郁胶囊治疗卒中后抑郁与氟西汀相当,疗效确切,不良反应明显少于后者。
Objective: To observe the efficacy and side effects of Shugan Jieyu capsule in the treatment of post-stroke depression. Methods: 120 patients with post-stroke depression were randomly divided into treatment group and control group. Both groups were given conventional treatment of cerebral infarction. The treatment group took Shugan Jieyu capsule while the control group took fluoxetine capsule for 8 weeks. The Hamilton Depression Rating Scale (HAMD) and TESS were used to evaluate the efficacy and adverse reactions at the end of the second, fourth and eighth weeks of treatment before treatment. Results: By the end of the study, the HAMD scores of both groups were significantly lower than those before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). The effective rates of treatment group and control group were 86.67% 83.33%, the difference was not statistically significant (P> 0.05). The TESS score of the treatment group was significantly lower than that of the control group (P <0.05). Conclusion: Shugan Jieyu Capsule is equivalent to fluoxetine in treating post-stroke depression with definite curative effect and less adverse reaction than the latter.